While the inherent pharmacokinetic properties of each GLP-1 receptor agonist largely determine elimination time, several patient-specific factors can influence how quickly or slowly these medications clear from the body
Along with preclinical data indicating that long-acting GIPR agonists act in the brain to decrease body weight and food intake via GIPR signalling in inhibitory -aminobutyric acid-producing (GABAergic) neurons 5,6,7 , and by mitigating the emetic effects of GLP-1R agonism 8,9 , GIPRGLP-1R co-agonism has been established as a highly effective strategy for the management of obesity, type 2 diabetes and MASH
You don't get that good feeling from eating. It also helps with impulse control, addressing both the urge to snack and the satisfaction you get from it
Get trained in glp-1s and FDA-approved medical weight management treatments
For example, a client noticed she gained 5 pounds in a month post-GLP-1, despite workoutsher thyroid was the culprit
By starting with very low doses and titrating slowly, some practitioners believe patients may achieve metabolic benefits whilst minimising tolerability issues